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Abstract
Background: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) or the internal segment of the globus
pallidus (GPi) has been established as a highly effective symptomatic therapy for Parkinson’s disease (PD). An
intriguing biological aspect related to the DBS procedure is that a temporary contact establishes between surgical
instruments and the surrounding brain tissue. In this exploratory study, we took advantage of this unique context
to harvest brain material adhering to the stylet routinely used during surgery, and to examine the biological value
of these samples, here referred to as “brain tissue imprints” (BTIs).
Results: Nineteen BTIs from 12 STN- or GPi-electrode implanted patients were obtained in vivo during DBS surgery,
without any modification of the surgical procedure. Immunofluorescence analyses confirmed that our approach
allowed the harvesting of many neural cells including neurons harboring distinct neurotransmitter markers.
Shotgun proteomic and transcriptomic analyses provided for the first time molecular information from DBS-
associated brain samples, and confirmed the compatibility of this new type of sample with poly-omic approaches.
The method appears to be safe and results consistent.
Conclusions: We here propose BTIs as original and highly valuable brain samples, and DBS-related brain imprinting
as a new conceptual approach to biological research in living patients with PD.
Keywords: Parkinson’s disease, Deep Brain Stimulation, Brain Tissue Imprint, Histological analysis, Poly-omic
approaches
Background
Nearly four decades of intensive research have proved
yet unsuccessful at deciphering the aetiology and mecha-
nisms underlying nigral decay in Parkinson’s disease
(PD) [1–3], in spite of myriads of hypotheses that have
been proposed thus far [4]. Reasons for this ongoing un-
certainty are many, including the extensive use of animal
models only partly relevant to human PD [5] and the
conducting of hypothesis-driven protocols [6, 7] that
may be too narrow to disentangle the numerous mecha-
nisms likely at work in PD degeneration. Because
hypothesis-driven protocols based on animal models of
PD have failed somehow, more global and hypothesis-
free strategies have been undertaken in humans, possibly
the only source of biological and molecular information
truly relevant to PD [8]. Examples include genome-wide
association studies [9, 10] or omic approaches [11–13].
In PD, while various peripheral tissues or biological
fluids are easily amenable to collection in living patients,
relevant neural tissue can be obtained only at autopsy
from deceased patients. Indeed, during the last ten years
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or so, a number of proteomic and transcriptomic studies
have been conducted on post-mortem brain tissue sam-
ples from various PD-relevant brain structures [11, 14].
However, post-mortem samples are associated with a
number of limiting and confounding factors [15–17].
First, difficulties to obtain autopsy tissue [18] tend to
keep the number of available samples per study quite
low, thus minimizing statistical power to draw firm con-
clusions. Second, the quality of autopsy tissue is intim-
ately related to the duration and specificities of the pre-
mortem agonal state and post-mortem interval (PMI)
[19, 20]. Finally, with few exceptions, post-mortem sam-
ples are obtained from patients at an advanced stage of
disease, making it difficult to identify early molecular
events at the basis of the complex basal ganglia (BG)
electrophysiology and PD pathogenesis.
To overcome these limitations, and considering all is-
sues discussed above, it may seem that the ultimate sam-
ple for biological research in human PD is still to be
found. Ideally, it has to be safely and routinely obtained
from a large number of living individuals with well-
documented sporadic PD. It should consist of biological
material directly involved in PD pathogenesis, in this
case brain material. Methods to collect samples should
be standardized and sampling-to-freezer time should be
kept as short as possible.
While this may seem unrealistic at first glance, we
propose a novel strategy to obtain PD-relevant samples
that may approximate these requirements, based on the
concept of in vivo brain tissue imprinting during electrode
implantation for deep brain stimulation (DBS) [21]. In
fact, we hypothesized that, during this procedure, brain
material of interest may adhere to surgical instruments,
which transiently interact with implanted nuclei and can
be retrieved and analysed at the cellular and molecular
level, for example through omic strategies. In this study,
we demonstrate for the first time the feasibility, safety,
and scientific interest of collecting and studying such
DBS-associated samples, here referred to as brain tissue
imprints (BTIs), which may provide unique biological sig-
natures of deep brain structures, and, in our opinion, may
represent a new paradigm in PD research using highly
relevant brain material from living patients.
Results
Brain tissue imprinting of BG nuclei
In this study, 12 patients have been offered bilateral elec-
trode implantation [22] in STN or GPi to alleviate their
motor symptoms (Table 1). Once the optimal target site
for the chronic electrode to be implanted has been de-
fined, neurosurgeon A or B lowered a blunt stylet inside
a guiding tube (Fig. 1a), to the neuroimaging-defined tar-
get site (Fig. 1b). First, the radiographic projection on
the patient’s preoperative brain MRI confirmed that the
stylet tip was within the surgical target, i.e. the STN or
GPi (Fig. 1c). The surgeon kept the stylet tip exposed
Table 1 Patient information and clinicopathological data of human BTIs
Patients Gender Age, yr Disease duration, yr Implanted nuclei Neurosurgeon BTI number Left (L) or Right (R) Experiment
P1 F 41 6 STN A L1 SEM
R1 CB-IHC
P2 F 60 10 STN B L2 CB-IHC
R2 CB-IHC
P3 M 52 8 STN A L3 P
R3 T
P4 M 53 7 STN B L4 T
R4 T
P5 M 46 6 STN A L5 P
P6 M 54 11 STN B R6 P
P7 M 61 9 STN B L7 P
R7 P
P8 M 53 9 GPi B L8 P
R8 P
P9 F 45 10 GPi A L9 P
P10 M 69 14 GPi A L10 P
P11 F 59 12 GPi A L11 P
P12 M 52 11 GPi B R12 P
Eight men (M) and 4 women (F) had been offered DBS in STN or GPi by neurosurgeon A or B. BTIs were obtained from left (L) or right (R) hemisphere and used
for scanning electron microscopy (SEM), cellblock immunohistochemical (CB-IHC), proteomic (P) or transcriptomic (T) analyses
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one minute into the patient brain before withdrawing it
through the guide tube, and finally removed the set from
the brain parenchyma. From the 12 bilaterally implanted
patients, a total of 19 stylets was collected and tips that
harvested tissue fragments as observed with scanning
electron microscopy (Fig. 1d) were immersed in appro-
priate buffer for further analyses (Table 1). No immedi-
ate or late complication from the procedure could be
identified. These data demonstrate that the transient
contact of the stylet tip with DBS targeted nuclei allows
brain material harvesting with no significant modifica-
tion of the routine DBS procedure.
Confirming the capture of neural cells by
immunohistochemical analyses
To characterize these tissue fragments and confirm the
capture of neural cells, three different STN-associated
stylet tips were collected in fixative solution for immu-
nohistochemical analyses. First, a hematoxylin-eosin
staining revealed the presence of numerous cells in these
tissue fragments, variably clustered throughout the sam-
ple (Additional file 1: Figure S1). The neuronal and glial
nature of these cells was confirmed by immunohisto-
chemical analyses using β3-Tubulin or NeuN, and GFAP
monoclonal antibody, respectively (Fig. 2). In fact, β3-
Tubulin (Fig. 2a) and NeuN (Fig. 2B and Additional file 1:
Figure S1) staining from 10 μm-thick sections revealed
the presence of many positive cells whereas GFAP staining
(Fig. 2b and Additional file 1: Figure S1) highlighted an
important astroglial network. In addition, V-GLUT1
(Fig. 2e) and GAD67 (Fig. 2f) immunostaining demon-
strated the presence of glutamatergic and GABA-ergic
neurons, respectively, and we also observed the presence
of large TH-immunoreactive patches lacking nuclei.
These experiments confirm that DBS-obtained tissue
fragments contain, besides astrocytes, neurons and fibers
harbouring various neurotransmitter markers and reflect
brain tissue of BG origin. We defined this collected ma-
terial as brain tissue imprints (BTIs).
Quantifying extracted proteins from STN and GPi-
associated BTIs
Before to envisage potential proteomic studies, it ap-
peared important to determine the BTI-collected protein
quantity, which, if too low, could be a limiting factor of
our approach. For this purpose, 12 blunt stylets that
were lowered in the STN (n = 6) or GPi (n = 6) by neuro-
surgeon A or B (Table 1) were collected. First, the Brad-
ford protein assay of the 12 samples varied from 6.8 to
17.5 μg of proteins with a mean capture of 10.2 ± 3.6 μg
Fig. 1 The BTI procedure. a The set combines a guide tube and a rigid blunt stylet. The stylet slides through the guide tube and its tip protrudes
by 1.5 mm out of the guiding tube. b-c The stylet tip is lowered to the targeted nucleus (here the GPi) and interacts with the brain parenchyma
according to (b) the perioperative radiographic control and (c) the pre-operative MRI-defined trajectory. d Scanning electron microscopy of the
stylet tip-associated tissue revealed the presence of cell bodies and fibers
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of proteins. The comparison between STN and GPi-
associated BTIs revealed no statistical difference between
he different nuclei with 11.4 ± 4.4 and 8.9 ± 2.4 μg re-
spectively (Mann Whitney test, p = 0.47) (Fig. 3a). In
addition, we did not observe any significant difference
in extracted-protein quantity according to the neuro-
surgeon who collected the BTIs. In fact, BTIs
revealed 10.8 ± 4.1 and 9.6 ± 3.3 μg of proteins for
neurosurgeon A and B, respectively (Mann Whitney
test, p = 0.78), (Fig. 3a). These results suggest that
BTIs can be consistently obtained in any electrode-
implanted nucleus, are neurosurgeon-independent and
contain amounts of proteins suitable for any prote-
omic protocols.
Fig. 2 BTI-associated immunohistochemical analyses. Neuronal markers β3-tubulin (a) and NeuN (b) as well as astroglial marker GFAP (c) were identified in
BTIs. The presence of tyrosin hydroxylase (TH) was detected in regions poor in cell nuclei, suggesting the presence of TH-immunoreactive
axons (d). Glutamatergic (e) and GABA-ergic (f) β3-tubulin immunoreactive neurons were also detected (arrows). Scale bar: A = 160 μm, B =
20 μm, C = 90 μm, D = 85 μm, E and F = 30 μm
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Examining the detailed protein content of STN and GPi-
associated BTIs by shotgun proteomics
To obtain a qualitative protein profile of these imprints,
we separated by 1D electrophoresis both STN and GPi-
associated BTIs (Fig. 3b). First, all samples revealed com-
plex profiles with the presence of many protein bands on a
wide mass range, from 14 to 250 kDa. Moreover, for both
nuclei, the different BTIs revealed similar qualitative pro-
files with the presence of the same protein bands. Finally
the comparison of STN and GPi-associated BTIs did not
reveal obvious significant differences in protein profiles,
showing a reproducible overall protein pattern. To further
characterize STN and GPI-associated BTIs, 1D SDS-
PAGE fractionation was combined with nano-LC-MS/MS
analysis for extensive protein identification. Nano-LC-MS/
MS analysis of STN-associated BTIs allowed the identifica-
tion of 1’081 different proteins. The analysis of GPI-
associated BTIs revealed 894 different proteins. Combin-
ing both protein lists highlighted a total of 1’298 distinct
proteins (Additional file 2: Table S1). Among the 1’298
identified proteins, we observed neuron, astrocyte and
oligodendrocyte-enriched proteins such as neuronal
growth regulator 1, astrocytic phosphoprotein PEA-15
and myelin-oligodendrocyte glycoprotein (Table 2). We
also identified proteins implicated in different nervous
cell functions such as cell architecture, cell adhesion,
synapse organization or neural maturation. Finally, con-
sistent with immunofluorescence data detailed above,
we also observed neurotransmitter-associated receptors
and transporters such as glutamate receptor 2,
metabotropic glutamate receptor 3 and vesicular glu-
tamate transporter 1. These results confirmed the suit-
ability of BTI to explore in depth the structural and
functional proteome of different electrode-implanted
nuclei.
Functional analysis of BTI-identified proteins
To investigate the functional role of BTI-identified pro-
teins, we separately submitted STN and GPi protein lists
to Ingenuity Pathway Analysis Software (IPA) [23]. This
automated annotation tool uses a knowledge database
and assigns proteins to functional classes or specific ca-
nonical pathways related to various biological processes.
To confirm the relevance of our BTI approach, we deter-
mined the relative representation of neurological dis-
eases and brain-associated signalling pathways in STN
and GPi-associated BTIs, respectively. First, the func-
tional analysis revealed neurological diseases and psy-
chological disorders as the two most represented
disorders in both types of BTIs (Fig. 4a). In fact, STN
and GPi protein lists respectively revealed 412 and 381
different species associated to neurological disease path-
ways, which represented 38.1 and 42.6 % of the total
identified proteins in STN and GPi, respectively. More-
over, among these neurological disease-associated pro-
teins, 69 and 56 species, which represented 6.4 and 6.3 %
of the total identified proteins, were associated to PD in
STN and GPi-BTIs, respectively. Finally, we also observed
that canonical pathways (CPs), which were specific to
brain functionality such as synaptic long term potentiation
Fig. 3 a BTI-extracted protein quantity. Scatter plot showing the quantity of proteins extracted from BTIs according to the targeted nucleus (up)
and to the surgeon (bottom). b 1D SDS-PAGE electrophoresis of STN (top) and GPi (bottom) –associated BTIs. Two micrograms of proteins were
loaded on 15 % polyacrylamide gel and revealed by silver staining
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and neurotransmitter signalling pathways, or described as
altered in PD such as mitochondrial dysfunction, oxidative
phosphorylation and axonal guidance associated pathways
were significantly represented (p-value < 0.05) in both
types of BTIs (Fig. 4b). Of particular interest, PD signalling
was significantly represented in both type of BTIs with the
identification of several PD-relevant proteins such as α-
synuclein, DJ-1 protein, UCHL1 protein and VPS35 pro-
tein, within which mutations have been associated with
autosomal dominant or recessive forms of PD (Table 2).
In addition, the proportion of proteins that was associated
to these CPs were quite similar between the two types of
BTIs. These results demonstrate the ability of the BTI ap-
proach to highlight brain and PD-related functional signa-
tures in different nuclei and confirm that proteomics
analysis of BTIs could be an appropriate strategy to study
PD altered signalling pathways.
Confirming the extraction of high-quality RNA from STN-
associated BTIs
Given the major interest of gene expression profiling in
PD-associated research, we assessed the capacity of BTIs
Table 2 Brain-enriched and PD-associated proteins from BTIs.
Table listing the accession number in Unirot database (ID), the
isoelectric point (pI), the molecular weight (protein mass), and the









1 PEA15_HUMAN 4.9 15088 Astrocytic phosphoprotein
PEA-15
2 BASP1_HUMAN 4.6 22562 Brain acid soluble protein 1
3 CNRP1_HUMAN 5.2 14224 CB1 cannabinoid receptor-
interacting protein 1
4 GFAP_HUMAN 5.5 49880 Glial fibrillary acidic protein
5 GRIA2_HUMAN 7.6 96183 Glutamate receptor 2
6 PEBP1_HUMAN 7.8 21057 Hippocampal cholinergic
neurostimulating peptide
7 LSAMP_HUMAN 5.7 31818 Limbic system-associated
membrane protein
8 LYNX1_HUMAN 6.6 11937 Ly-6/neurotoxin-like
protein 1
9 GRM3_HUMAN 7.7 96386 Metabotropic glutamate
receptor 3
10 MBP_HUMAN 11.5 21493 Myelin basic protein
11 MYPR_HUMAN 8.8 29946 Myelin proteolipid protein
12 MOG_HUMAN 9.0 25110 Myelin-oligodendrocyte
glycoprotein
13 NCAM1_HUMAN 4.8 92408 Neural cell adhesion
molecule 1
14 NCAM2_HUMAN 5.5 91052 Neural cell adhesion
molecule 2
15 L1CAM_HUMAN 5.8 137831 Neural cell adhesion
molecule L1
16 NCALD_HUMAN 5.4 22114 Neurocalcin-delta
17 NCAN_HUMAN 5.2 140732 Neurocan core protein
18 NCDN_HUMAN 5.4 77243 Neurochondrin
19 NFASC_HUMAN 6.6 130112 Neurofascin
20 NFH_HUMAN 5.8 105639 Neurofilament heavy
polypeptide
21 NFL_HUMAN 4.6 61385 Neurofilament light
polypeptide
22 NFM_HUMAN 4.9 102341 Neurofilament medium
polypeptide
23 NEUM_HUMAN 4.7 24803 Neuromodulin
24 NRCAM_HUMAN 5.7 130668 Neuronal cell adhesion
molecule
25 NEGR1_HUMAN 6.5 31426 Neuronal growth regulator 1
26 GPM6A_HUMAN 5.7 29905 Neuronal membrane
glycoprotein M6-a
27 GPM6B_HUMAN 5.9 36220 Neuronal membrane
glycoprotein M6-b
28 SEPT3_HUMAN 6.5 40100 Neuronal-specific septin-3
29 NPTN_HUMAN 7.6 37792 Neuroplastin
30 NTRI_HUMAN 6.0 31738 Neurotrimin
31 SYN1_HUMAN 9.9 70033 Synapsin-1
32 SYN2_HUMAN 8.7 62847 Synapsin-2
33 SYN3_HUMAN 9.5 63303 Synapsin-3
Table 2 Brain-enriched and PD-associated proteins from BTIs.
Table listing the accession number in Unirot database (ID), the
isoelectric point (pI), the molecular weight (protein mass), and the
name (description) of different brain-enriched or PD-associated
proteins (bold) (Continued)
34 SV2A_HUMAN 5.4 82695 Synaptic vesicle
glycoprotein 2A
35 SNG3_HUMAN 8.8 24555 Synaptogyrin-3
36 SYNJ1_HUMAN 7.1 143254 Synaptojanin-1
37 SYPH_HUMAN 4.7 33845 Synaptophysin
38 SNP25_HUMAN 4.7 23315 Synaptosomal-associated
protein 25
39 SYT1_HUMAN 8.4 47573 Synaptotagmin-1
40 VGLU1_HUMAN 7.6 61613 Vesicular glutamate
transporter 1
41 VAMP1_HUMAN 8.7 12658 Vesicle-associated
membrane protein 1
42 VAMP2_HUMAN 8.9 12532 Vesicle-associated
membrane protein 2
43 GMFB_HUMAN 5.3 16582 Glia maturation factor beta
44 SYNPO_HUMAN 9.4 73666 Synaptopodin
45 SYUG_HUMAN 4.9 13330 Gamma-synuclein
46 SYUB_HUMAN 4.5 14288 Beta-synuclein
47 SYUA_HUMAN 8.8 11371 Alpha-synuclein
48 PARK7_HUMAN 6.8 19891 Protein DJ-1
49 UCHL1_HUMAN 5.5 24824 Ubiquitin carboxyl
terminal hydrolase
isozyme L1
50 VPS35_HUMAN 5.4 91707 Vacuolar protein
sorting-associated pro-
tein 35
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to extract good quality RNAs from in vivo STN nucleus
in PD patients. For this purpose, three different STN-
stylets were collected, total RNA was extracted from
these BTIs, and we applied a double amplification proto-
col to generate sufficient biological material for further
analysis. After amplification rounds, these three BTIs re-
vealed between 65 and 200 μg of RNAs, i.e. quantities
appropriate for hybridization microarray analysis. To con-
firm the good quality of BTI-extracted RNAs, we applied
the same preparation protocol on brain cortical sections
obtained during epilepsy surgery and used as high-quality
control sample. For this control sample, given the availabil-
ity of sufficient starting material, the RNA quality was con-
trolled and confirmed before amplification by capillary
electrophoresis migration, which revealed full length RNAs
and RNA integrity number (RIN) of 8.3 (Additional file 3:
Figure S2). After a double amplification round, the control
sample naturally revealed electrophoretic profile with
shorter products that we compared with the BTI-obtained
profiles. As shown on Fig. 5a, we observed a great similarity
between BTI and control electrophoretic profiles with same
length RNAs, implying that similarly to the control sample,
BTI-collected RNAs were also full length and intact before
amplification. These results demonstrate that high quality
RNAs can be retrieved in vivo from DBS-targeted nuclei
and are suitable for microarray analyses.
Given the sufficient quantity and the good quality of
extracted RNAs, the samples were separately hybridized
on microarrays to determine the complexity of expressed
transcripts in BTI samples. Detailed results are available
in Additional file 4: Table S2. The analysis of BTI-
extracted RNAs highlighted from 29’842 to 35’701 differ-
ent detected probe sets, which corresponded to a chip
hybridization rate from 54.5 to 65 % (Fig. 5b). A chip
hybridization rate of 60 % was obtained for the control
sample, the analysis of which revealed 33’073 detected
probe sets. Moreover the qualitative analysis of the BTI-
associated chips revealed 26’112 common detected
probe sets in the different BTIs, suggesting a robust
qualitative reproducibility of the BTI approach. More-
over intensities of these common detected probe sets
were strongly correlated between the different samples
(Fig. 5c). In fact, the graphical representation of the
26’112 probe sets intensities in the different BTIs re-
vealed a Pearson’s correlation coefficient of 0.8 to 0.9
with a slope value between 0.97 and 1.0, suggesting that
most of these common probe sets were similarly
expressed in the different BTIs, which originated from
the same type of brain structure in the same disease
condition. Altogether, these results demonstrate that
high quality transcriptomic analyses may be undertaken
from our BTI approach.
Discussion
Accessing in vivo human brain samples for PD-
associated research has long been considered an unreal-
istic approach, yet it may be one of the most relevant
strategies to address such pivotal issues as etiopatho-
genic events, molecular pathways and diagnostic or
therapeutic biomarkers. Since its first use in the ventral
intermediate nucleus of the thalamus by Benabid et al.
[24], DBS in PD has been extended to STN [25], GPi
[26] and other deep brain nuclei [27], and has become
the mainstay of surgical therapies to manage motor
symptoms at early to advanced stages of the disease.
In the present study, we demonstrate for the first time
that DBS-associated electrode implantation offers a
unique opportunity to obtain in vivo fresh tissue im-
prints from relevant and electrophysiologically active
deep brain structures. In fact, the stylet that is systemat-
ically used in DBS surgery, the tip of which is in imme-
diate contact with the surrounding tissue, allows to
recover, irrespective of brain targets and surgeons, tissue
micro fragments that we have defined as BTIs. This un-
conventional material seems to be highly informative
Fig. 4 Functional analysis of the STN and GPi protein lists by Ingenuity
Pathway Analysis. a Proportion of proteins associated to neurological,
psychological and PD in STN and GPi protein lists, respectively. The
data at the top of each bar correspond to the number of proteins
associated to the disease. b Signalling pathways associated to brain
functions and known to be altered in PD, and significantly represented
in the STN and GPi protein lists (−log p-value > 1.3 i.e. p-value < 0.05)
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and of great scientific interest. Indeed, immunohistologi-
cal analyses of STN-derived BTIs consistently showed
populations of glutamatergic and GABAergic neurons,
and the presence of TH-immunoreactive fibers, as ex-
pected in the STN-SN region [28]. Whereas the SN pars
reticulata mainly contains large GABAergic projecting
neurons, the STN is populated with glutamatergic
neurons, some of which collateralizing locally and some
receiving TH projections from SNpc-associated dopamin-
ergic neurons [29]. Our findings are therefore in accord-
ance with the current anatomical knowledge of these
structures. Moreover, omic analyses of BTIs allowed to
profile extensively their proteome and transcriptome,
yielding lists of proteins and transcripts that turned out to
be highly relevant for neurological diseases in general and
PD in particular. Altogether, these preliminary results
strongly support the concept of brain tissue imprinting
during DBS surgery and the potential of this unique brain
material to undergo informative poly-omic analyses.
The research paradigm proposed in this study is new
and demonstrates many advantages over more conven-
tional methods using post-mortem samples. First, the
method of collecting BTIs is convenient and simple to
perform in the context of DBS surgery, as it does not
modify the DBS procedure. Second, this strategy proposes
an in vivo access to deep brain nuclei and the collection of
samples that are immediately processed in the surgical
room within minutes after being captured, thus minimiz-
ing protein or RNA degradation [19, 20]. Moreover, BTIs
are obtained in awaken and off-medication patients, ac-
cording to the routine DBS procedure, thus limiting the
potentially deleterious influence of anaesthesia and anti-
parkinsonian medication, respectively, on molecular me-
tabolism. Third, BTIs being collected from highly selective
Fig. 5 Transcriptomic analysis of BTI-extracted RNAs. a Quality control of BTI-extracted RNA by capillary electrophoresis migration. The electrophoretic
profiles of the BTI-samples were compared with a high-quality control sample. b Microarray hybridization of the BTIs. Venn diagrams representing the
number of detected and common probe sets in BTI samples by microarray analysis. c Intensity correlation for the common detected probe sets in the
3 BTIs. Linear regression curve representing the intensity of expression of common probe sets in the three BTIs. The coefficient of correlation (r) and
the coefficient of the slope is dysplayed on the graphe
Zaccaria et al. Molecular Neurodegeneration  (2016) 11:12 Page 8 of 13
brain structures, in this particular case BG nuclei, seem
particularly relevant to address functional and structural
issues related to the underlying pathology. As far as PD is
concerned, electrode implantation usually occurs 10 to
12 years after PD diagnosis, and performing BTIs in this
context would ensure the access to a homogeneous group
of PD brains at an earlier stage of disease than post-
mortem samples, which often derived from patients diag-
nosed 15 to 25 years prior to death. Furthermore, the re-
cent use of DBS much earlier in the disease course, 5 to
7 years after diagnosis [30], opens the door to BTI-derived
studies on molecular changes occurring only a few years
after PD has started. Also, as DBS is currently exploring
many other indications, including epilepsy, Alzheimer’s
disease, obsessive-compulsive disorders, Gilles de la Tour-
ette syndrome, depression, and many others, this ap-
proach may likely be transposed to any DBS-treated
neurological [31] or psychiatric diseases [32]. Fourth, an-
other advantage of our approach involves the number of
samples that could be collected, which is virtually unlim-
ited, as opposed to post-mortem samples which are no-
toriously difficult to obtain. Furthermore, if various
conditions are operated, stratification of samples accord-
ing to pathologies or nuclei, and statistically powerful
comparisons of results across groups, one serving as con-
trol for the other may become possible.
The BTI method proposed here is in a preliminary
phase and may have some limitations, yet solutions to
circumvent them can be already considered. First, the
biological material composing BTI samples is likely het-
erogeneous, involving various cell types, neuronal popu-
lations, dendrites, axons and other cellular extensions,
synapses and other contacts between cells, blood vessels,
extracellular fluid and so on, thus lacking cellular or
subcellular specificity. While this may seem problematic,
it may also be beneficial in providing a global view of
the molecular state of the structure considered at a cer-
tain time point. Second, only existing surgical tools were
used in this study, with the purpose of not modifying
the routine procedure of DBS, yet it is possible that BTIs
were contaminated by unwanted material during the
descent of the stylet. In the future, new BTI-specific in-
struments and protocols may be designed to achieve an
even more selective imprint and high-grade BTI purity.
Third, whereas molecular analysis of STN and GPi-
obtained BTIs may be of interest to investigate func-
tional changes occurring in PD, other structures bearing
alpha-synuclein pathology, like the SNpc, might be more
relevant to address pathogenesis. Indeed, because the SN
lies anatomically just below the STN, it is not unusual
for the tip of the DBS electrode to be placed within
the SN [33], and we therefore assume that BTIs can also
be captured from this pivotal structure in certain
patients.
Finally, at variance with post-mortem samples that can
be collected both in diseased and normal states, DBS-
associated BTIs can only be obtained in pathological,
DBS-treatable conditions and will never concern healthy
patients. To circumvent this important limitation, we
propose to use a variety of non-degenerative conditions
where DBS targeting of the same structures is also indi-
cated. For example, PD-associated BTIs from STN, GPi
or VIM may be compared with matching BTIs from
non-PD conditions such as OCD and epilepsy (STN),
dystonia and Gilles de la Tourette syndrome (GPi), and
essential tremor (VIM) respectively [34–38]. Moreover,
the application of DBS in PD patients with different dis-
ease durations, from 5 to 15 years may enable the strati-
fication of BTIs according to disease duration and
disease stages, and the comparison of early versus late
biological changes potentially occurring in the basal gan-
glia. Finally, as PD is an asymmetrical disease and as
BTIs could be collected bilaterally, comparisons may
involve less versus more affected basal ganglia struc-
tures for each patient. Thus, several options are avail-
able to obtain comparative samples. While they may
not totally fulfil the definition of control samples,
they are likely to be sufficiently distinct from PD to
allow robust and meaningful comparative analyses to
be performed.
Conclusion
In conclusion, this exploratory, proof-of-concept study
proposes in vivo DBS-associated brain tissue imprinting as
an original paradigm to explore the cellular and molecular
profile of deep brain nuclei in human PD, and likely in any
degenerative and non-degenerative DBS-treated neuro-
logical and psychiatric conditions. In particular, the bio-
logical material obtained through this approach appears to
overcome most of the limitations inherent to post-mortem
tissue and to be particularly suitable for omic research.
Taking into account these aspects, BTI may become the
ultimate sample of biological brain research in humans
and significantly impact on future studies on pathogenesis,
pathophysiology, biomarkers or therapeutic interventions
in various neurological disorders.
Methods
Study participants
Twelve patients have been offered bilateral STN (n = 7)
or GPi (n = 5) electrode implantation to alleviate their
motor symptoms at the University Hospital of Grenoble.
The STN-implanted group was 41 to 61 years (mean:
52.4 ± 7.1 years) and included five men and two women.
The GPi-implanted group was 45 to 69 years (mean:
55.6 ± 8.9 years) and included three men and two
women. Two different surgeons performed electrode
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implantations irrespective of the chosen target. Surgeon
A performed 3 STN and 3 GPi electrode implantations.
Surgeon B performed four STN and two GPi electrode
implantations. Table 1 recapitulates the clinical and sur-
gical characteristics of each patient.
Patients gave clear informed consent to participate in
this study and we followed strict ethical guidelines given
by the Comite Consultatif National d’Ethique (The
French National Review Committee).
Neurosurgical procedure
STN or GPi electrode implantations were performed
with the ROSA stereotactic robot [22] (Medtech, Mont-
pellier, France) at the University Hospital of Grenoble.
Briefly, STN or GPi targeting was based on stereotactic
3 T magnetic resonance imaging (MRI) scan, which were
imported into the planning station and reformatted into
a plane parallel to the AC-PC plane by using robot plan-
ning software (ROSA from Medtech, Montpellier,
France). This first step allowed determining an entry
point while avoiding vessels of the cortical surface and
the sulci. Then, under local anaesthesia, three to five
parallel recording/stimulating microelectrodes each one
into a guiding tube, and on a “BenGun” system were
inserted into the brain using a motorized microdrive
(Alpha-Omega, Nazareth, Israel) on a ROSA stereotactic
robotic arm. The neuronal recording aimed to detect the
target, based on its typical firing pattern and was
followed by acute stimulation tests to determine the best
site for the chronic electrode to be placed. Finally the
chronic electrode (Medtronic, Minneapolis, USA) was
implanted and connected to the pulse generator (Med-
tronic, Minneapolis, USA).
Brain imprinting procedure
Once the best location for implantation of the definitive
electrode has been defined, microelectrodes were re-
moved from the guiding tube and replaced by a 1 mm-
diameter, stainless steel blunt stylet (Dixi, Besancon,
France), which slides through the guiding tube, pro-
trudes by 1.5 mm out of it, and reaches the target in 10
to 15 s (Fig. 1a). The stylet tip was kept 1 min in contact
with brain tissue to allow the imprinting process. To de-
termine the location of the stylet tip into the brain dur-
ing the imprint, intraoperative radiography (Fig. 1b) was
performed and merged with the patient pre-operative
MRI (Fig. 1c) using the robot planning software (ROSA
from Medtech, Montpellier, France). The stylet was then
retracted into the guiding tube so that the set can be
withdrawn in 5 to 10 s without the stylet tip being con-
taminated during the removal step. Once the set had
been removed from the brain, the stylet tip was immedi-
ately immersed in appropriate buffer for further analyses.
From the 12 operated patients, a total of 19 different
BTI samples were made available for the present study.
BTIs could not be performed in 5 hemispheres due to
technical constraints.
Nineteen different brain tissue imprints (BTI) had
been collected by surgeon A (n = 10) and B (n = 9) and
analysed by scanning electron microscopy (n = 1), immu-
nohistochemistry and immunofluorescence (n = 3), pro-
teomics (n = 12) and transcriptomics (n = 3) approaches.
Table 1 recapitulates the type of analysis performed on
each imprint.
Scanning electron microscopy
One stylet was collected in the surgical room and tissue
fragments that adhered to the stylet tip was collected in
fixative solution, dehydrated through an ascending serie of
ethanol solution and critical point dried using CO2. Tissue
fragments were sputter-coated with gold prior to examin-
ation in a Cambridge S360 scanning electron microscope.
Immunohistochemistry analyses
Stylets (n = 3) were collected in the surgical room and
their tip was immediately immersed in fixative solution
and cell block preparation was performed using the Shan-
don™ cytoblock™ preparation system (Thermo Fisher Sci-
entific, MA, USA) according to the manufacturer’s
protocol. Immuno-histofluorescence staining was per-
formed on de-paraffinized BTIs 10 μm thick sections
using antigen retrieval treatment and with secondary anti-
bodies coupled with Alexa fluorochrome (A488 or A555).
Neuronal and astroglial expression were identified using
β3-tubulin (Covance, PRB435P) or NeuN (Millipore,
MAB377) antibodies, and GFAP (DAKO, Z334) antibody,
respectively. Further neuronal phenotypic characterization
was investigated using antibody against: tyrosine hydroxy-
lase (TH, Chemicon, AB152), vesicular glutamate trans-
porter 1 for glutamatergic neurons (V-Glut1, Chemicon,
MAB5502), glutamic acid decarboxylase-67 (GAD-67,
Chemicon MAB5406) for GABA-ergic neurons. Sections
were then counterstained with DAPI to label cell nuclei.
Images were obtained using a fluorescence microscope
Zeiss 5.1 (Zeiss, Iena, Germany) coupled to a digital cam-
era and Axiovision 4.8 software (Zeiss).
Proteomic analysis
Sample treatment
Stylets (n = 12) were collected in the surgical room and
the stylet tip was immersed and kept under agitation
5 min at 4 °C in urea 8 M/CHAPS 2 % lysis buffer
(Sigma-Aldrich, Saint-Louis, MO, USA). Samples were
centrifuged 10 min at 10,000 g at 4 °C and the super-
natant was recovered and frozen at −80 °C until analysis.
For all samples, the delay between collection, protein ex-
traction and freezing was less than 1 h to prevent pro-
tein degradation.
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1D SDS-PAGE electrophoresis
The total protein amount recovered from each BTI was
quantified by the Bradford protein assay (Bio-Rad La-
boratories, Hercules, CA, USA). Two micrograms of
proteins from each BTI were individually mixed to
Laemmli buffer from Bio-Rad. The mixture was heated
in boiling water for 5 min and loaded on 15 % polyacryl-
amide gels. Staining was performed with 0.2 % silver ni-
trate solution for 2 min and protein bands were revealed
in 0.02 % formaldehyde/ 0.005 % citric acid solution.
Revelation was blocked with 1 % acetic acid solution and
gels were scanned.
In-gel fractionation
For both STN and GPi, 2.5 μg of proteins from six dif-
ferent BTIs were pooled, and the resulting 15-μg total
proteins were mixed to Laemmli buffer. The mixture
was heated in boiling water for 5 min and loaded on a
precast 4 to 20 % polyacrylamide gel from Bio-Rad.
Staining and destaining were performed with Coomassie
blue and 30 % ethanol/ 7 % acetic acid in water respect-
ively. STN and GPI-associated lanes were cut into 12
homogeneous fractions that were washed in 100 mM
ammonium bicarbonate for 15 min at 37 °C followed by
a second wash in 100 mM ammonium bicarbonate,
acetonitrile (1:1) for 15 min at 37 °C. Reduction and al-
kylation of cysteines were per- formed by mixing the gel
pieces in 10 mM DTT for 35 min at 56 °C followed by
55 mM iodoacetamide for 30 min at room temperature
in the dark. An additional cycle of washes in ammonium
bicarbonate and ammonium bicarbonate/acetonitrile was
then performed. Proteins were digested by incubating
each gel slice with modified sequencing grade trypsin
(Promega) in 50 mM ammonium bicarbonate overnight at
37 °C. The resulting peptides were extracted from the gel
by three steps: a first incubation in 50 mM ammonium bi-
carbonate for 15 min at 37 °C and two incubations in
10 % formic acid, acetonitrile (1:1) for 15 min at 37 °C.
The three collected extractions were pooled with the ini-
tial digestion supernatant, dried in a SpeedVac, and resus-
pended with 12 μl of 5 % acetonitrile, 0.1 % formic acid.
Nano-LC-MS/MS analysis
Protein identification of each fraction was performed by
nano-liquid chromatography tandem mass spectrometry
(nano-LC-MS/MS) and each fraction was analysed twice
to obtain technical replicates and to increase protein
identification.
Nano-LC-MS/MS was performed on a linear trap
quadrupole (LTQ) Orbitrap Velos Pro (Thermo Elec-
tron, San Jose, CA, USA) equipped with a NanoAcquity
system (Waters). Peptides were trapped on a home-
made 5 μm 200 Å Magic C18 AQ (Michrom) 0.1 ×
20 mm pre-column and separated on a commercial
0.075 × 150 mm Nikkyo (Nikkyo Technology) analytical
nanocolumn (C18, 5 μm, 100 Å). The analytical separ-
ation was run for 65 min using a gradient of H2O/FA
99.9 %/0.1 % (solvent A) and CH3CN/FA 99.9 %/0.1 %
(solvent B). The gradient was run as follows: 0–1 min
95 % A and 5 % B, then to 65 % A and 35 % B for
55 min, and 20 % A and 80 % B for 65 min at a flow rate
of 220 nL/min. For MS survey scans, the orbitrap (OT)
resolution was set to 60000 and the ion population was
set to 5 × 105 with an m/z window from 400 to 2000. For
protein identification, up to eight precursor ions were se-
lected for collision-induced dissociation (CID) in the LTQ.
The ion population was set to 1 × 104 (isolation width of
2 m/z) while for MS/MS detection in the OT, it was set to
1 × 105 with an isolation width of 2 m/z units. The nor-
malized collision energies were set to 35 % for CID.
Peptide and protein identification
MS data were processed using EasyProtConv. For each
imprinted nucleus, the peak list of each fraction was
generated from raw data CID spectra using the Easy-
ProtConv conversion module. The peak lists of all frac-
tions were then merged into a single peak list file per
nucleus on EasyProtConv. The two different obtained
peak lists were submitted to Easyprot, a platform that
uses Phenyx (GeneBio, Geneva, Switzerland) for protein
identification [39]. Searches were conducted against Uni-
Prot Swiss-Prot database (669 903 entries on October,
2014) specifying Homo sapiens taxonomy. Specificity of
trypsin digestion was set for cleavage after Lys or Arg
except before Pro, and two missed trypsin cleavages
were allowed. Carbamidomethylation of cysteines was
set as a fixed modification, and oxidation of methionine
was set as variable modifications. Peptide z-scores were
then set to maintain a false positive peptide ratio below
1 %. Proteins with at least two distinct peptide sequences
were automatically validated. Proteins were clustered
based on shared peptides, with the protein entry con-
taining the most peptides selected as the group reporter.
Functional analysis by ingenuity pathway analysis
The STN and GPI-associated protein lists were further
submitted to Ingenuity Pathway Analysis software (In-
genuity Systems, Redwood City, CA) to perform the
functional characterization of the proteins recovered
from the BTIs. This automatic annotation tool uses a
knowledge database and assigns proteins to functional
classes or specific canonical pathways (CPs) related to
various biological processes [23].
Transcriptomic analysis
RNA extraction, amplification and quality control
STN-associated BTIs (n = 3) were collected in the surgical
room and quickly immersed and kept under agitation
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5 min in 100 μl lysis buffer from the mirVana isolation
kit™ (Ambion, Applied Biosystems, Foster City, CA) to
prevent RNase activity and therefore to limit RNA degrad-
ation. In parallel, two 60 μm-thick sections from a cortical
piece, which was obtained during a previous surgical tis-
sue resection in an epilepsy patient, were cut at −20 °C
and immediately immersed in 100 μl lysis buffer. This
sample was used as a technical control. After tissue lysis,
total RNA was isolated from BTI and technical control
using a phenol:chloroform extraction protocol (MirVana
isolation kit™, Ambion, Applied Biosystems). Before RNA
amplification, the quality and integrity of the technical
control were confirmed (RNA integrity = 8.3, suppl data 2)
by capillary electrophoresis migration using RNA nano
6000 kit and the Bioanalyzer 2100 (Agilent Technologies,
Palo Alto, CA). Then total RNAs from BTIs and technical
control were separately amplified with the GeneChip 3’
IVT Express Kit. First, total RNAs were reverse-transcribed
using primers polydT-T7 promoter sequence; cDNAs were
double-stranded synthesized and finally amplified by the
T7 RNA polymerase. A second amplification was per-
formed with WT-expression kit™ (Ambion, Applied Biosys-
tems, Foster City, CA) to obtain biotinylated cDNA. After
this double amplication procedure, the RNA concentration
of each BTI sample was determined with the measure of
absorbance at 260 nm, and the electrophoretic profiles of
BTI-samples were compared to the technical control to in-
directly confirm the quality of BTI-extracted RNA.
Microarray hybridization
Microarrays experiments were carried out in accordance
with the protocol GeneChip Expression Wash, Stain and
Scan from Affymetrix (Santa Clara, CA, USA). Briefly,
15 μg of labeled cRNA was hybridized for 16 h at 45 °C on
GeneChip Human Genome U133 Plus 2.0 (Affymetrix,
Santa Clara, CA, USA) corresponding to 54675 unique
gene probe sets. The arrays were washed and stained with
streptavidin − phycoerythrin before scanning. The fluores-
cence values of each probe set signal, reported in arbitrary
units, were processed with MAS5 statistical algorithm to
validate the probe set signal “absent” or “present”, and fi-
nally they were normalized between all the arrays using
the Robust Multichip Analysis (RMA) algorithm. These
algorithms are included in Affymetrix expression console
(Affymetrix, Santa Clara, CA, USA).
Additional files
Additional file 1: Figure S1. BTI-associated immunohistochemical
analyses. Immunostaining of the dilator-bound material (X200) revealed
(top) the presence of many cells by hematoxylin-eosin staining among
which (middle) neurons by neuronal nuclei (NeuN) staining and (bottom)
astrocytes by glial fibrillary acid protein (GFAP) staining. (DOCX 551 kb)
Additional file 2: Table S1. Non-redundant lists of the proteins
identified in STN or GPi-associated BTIs. (XLSX 401 kb)
Additional file 3: Figure S2. Confirmation of the technical control-
related RNA Integrity by capillary electrophoresis. (DOCX 191 kb)
Additional file 4: Table S2. Micro-array hybridization results. The table
recapitulates detected (P) and non-detected (A) transcripts in all analyzed
samples. (XLSX 12765 kb)
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